

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

CLINICAL BENEFIT	☐ MINIMIZE SAFETY RISK OR CONCERN. ☒ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. ☐ ASSURE APPROPRIATE LEVEL OF CARE. ☐ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. ☒ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. ☐ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	RETIRED 7/1/2026

[POLICY](#)
[RATIONALE](#)
[CODING INFORMATION](#)
[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[REFERENCES](#)
[DESCRIPTION/BACKGROUND](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

I. POLICY

Plasma-based proteomic screening, including but not limited to Nodify XL2® (BDX-XL2), Nodify CDT®, and REVEAL Lung Nodule Characterization (MagArray), in individuals with undiagnosed pulmonary nodules detected by computed tomography is considered **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

Gene expression profiling on bronchial brushings, including but not limited to Percepta® Genomic Sequencing Classifier, in individuals with indeterminate bronchoscopy results from undiagnosed pulmonary nodules is considered **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

Cross-Reference:

MP 2.337 Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO: Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

III. DESCRIPTION/BACKGROUND

[TOP](#)

Plasma-based proteomic screening and gene expression profiling of bronchial brushing are molecular tests available in the diagnostic workup of pulmonary nodules. To rule out malignancy, invasive diagnostic procedures such as computed tomography-guided biopsies, bronchoscopies, or video-assisted thoracoscopic procedures are often required, but each carry procedure-related complications ranging from post-procedure pain to pneumothorax. Molecular diagnostic tests have been proposed to aid in risk-stratifying patients to eliminate or necessitate the need for subsequent invasive diagnostic procedures.

Pulmonary Nodules

Pulmonary nodules are a common clinical problem that may be found incidentally on a chest x-ray or computed tomography (CT) scan or during lung cancer screening studies of smokers. The primary question after the detection of a pulmonary nodule is the probability of malignancy, with subsequent management of the nodule based on various factors such as the radiographic characteristics of the nodules (e.g., size, shape, density) and patient factors (e.g., age, smoking history, previous cancer history, family history, environmental/occupational exposures). The key challenge in the diagnostic workup for pulmonary nodules is appropriately ruling in patients for invasive diagnostic procedures and ruling out patients who should forgo invasive diagnostic procedures. However, due to the low positive predictive value of pulmonary nodules detected radiographically, many unnecessary invasive diagnostic procedures and/or surgeries are performed to confirm or eliminate the diagnosis of lung cancer.

Proteomics

Proteomics is the study of the structure and function of proteins. The study of the concentration, structure, and other characteristics of proteins in various bodily tissues, fluids, and other materials has been proposed as a method to identify and manage various diseases, including cancer. In proteomics, multiple test methods are used to study proteins. Immunoassays use antibodies to detect the concentration and/or structure of proteins. Mass spectrometry is an analytic technique that ionizes proteins into smaller fragments and determines mass and composition to identify and characterize them.

Plasma-Based Proteomic Screening for Pulmonary Nodules

Plasma-based proteomic screening has been investigated to risk-stratify pulmonary nodules as likely benign to increase the number of patients who undergo serial CT scans of their nodules (active surveillance), instead of invasive procedures such as CT-guided biopsy or surgery. Additionally, proteomic testing may also determine a likely malignancy in clinically low-risk or intermediate-risk pulmonary nodules, thereby permitting earlier detection in a subset of patients.

Nodify XL2® (BDX-XL2) is a plasma-based proteomic screening test that measures the relative abundance of proteins from multiple disease pathways associated with lung cancer using an analytic technique called multiple reaction monitoring mass spectroscopy. The test helps physicians identify lung nodules that are likely benign or at lower risk of cancer. If the test yields a "likely benign" or "reduced risk" result, patients may choose active surveillance via serial CT

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

scans to monitor the pulmonary nodule. Earlier generations of the Nodify XL2 test include Xpresys Lung® and Xpresys Lung 2®.

Nodify CDT® is a proteomic test that uses multi-analyte immunoassay technology to measure autoantibodies associated with tumor antigens. The test helps physicians identify lung nodules that are likely malignant or at higher risk of cancer. Patients with a “high level” Nodify CDT test result have a higher risk of malignancy than predicted by clinical factors alone; invasive diagnostic procedures would be indicated in these cases.

The Nodify XL2 and Nodify CDT tests are therefore only used in the management of pulmonary nodules to rule out or rule in invasive diagnostic procedures; they do not diagnose lung cancer. These tests are offered together as Biodesix’s Nodify Lung® testing strategy, but physicians may also choose to order each test independently.

REVEAL Lung Nodule Characterization (MagArray) is a plasma-protein biomarker test that may aid clinicians in characterizing indeterminate pulmonary nodules (4 to 30 mm) in current smokers 25 years of age and older. The test is based on a multianalyte assay with a proprietary algorithmic analysis using immunoassay, microarray, and magnetic nanoparticle detection techniques to obtain laboratory data for calculation of the risk score for lung cancer. The REVEAL Lung Nodule Characterization is presented on a scale from 0 to 100 with a single cut point at 50. The score is based on the measurement of 3 clinical factors (age, sex, and nodule diameter) and 3 proteins (epidermal growth factor receptor, prosurfactant protein B, and tissue inhibitor of metalloproteinases associated with the presence of lung cancer. It may aid a clinician in the decision to perform a biopsy or to consider routine monitoring. It is not intended as a screening or stand-alone diagnostic assay.

Gene Expression Profiling

Gene expression profiling (GEP) is the measurement of the activity of genes within cells. Messenger RNA serves as the bridge between DNA and functional proteins. Multiple molecular techniques such as Northern blots, ribonuclease protection assay, in situ hybridization, spotted complementary DNA arrays, oligonucleotide arrays, reverse transcriptase polymerase chain reaction, and transcriptome sequencing are used in GEP. An important role of GEP in molecular diagnostics is to detect cancer-associated gene expression of clinical samples to assess for the risk for malignancy.

Gene Expression Profiling for an Indeterminate Bronchoscopy Result

The first generation Percepta® Bronchial Genomic Classifier is a 23-gene, GEP test that analyzes genomic changes in the airways of current or former smokers to assess a patient’s risk of having lung cancer, without the direct testing of a pulmonary nodule. This classifier was designed to be a “rule-out” test for intermediate-risk patients. The second generation Percepta Genomic Sequencing Classifier was developed to serve as both a “rule-in” test and a “rule-out” test, thereby increasing its potential utility in improving risk stratification. The test is indicated for current and former smokers following an indeterminate bronchoscopy result to determine the

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

subsequent management of pulmonary nodules (e.g., active surveillance or invasive diagnostic procedures), and does not diagnose lung cancer.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Xpresys Lung 2, now Nodify XL2 (BDX-XL2; Integrated Diagnostics [Indi], purchased by Biodesix); Nodify CDT (Biodesix); REVEAL Lung Nodule Characterization (MagArray); and Percepta Genomic Sequencing Classifier (Veracyte) are available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of these tests.

IV. RATIONALE

[TOP](#)

Summary of Evidence

For individuals with undiagnosed pulmonary nodules detected by computed tomography who receive plasma-based proteomic screening, the evidence includes prospective cohorts, retrospective studies, and prospective-retrospective studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, morbid events, hospitalizations, and resource utilization. Clinical validation studies were identified for 2 versions (Xpresys Lung, and Xpresys Lung version 2 [now Nodify XL2]) of a proteomic classifier and another lung nodule characterization test (REVEAL). The Nodify XL2 classifier has undergone substantial evolution, from a 13-protein assay to a 2-protein assay integrated with clinical factors. Because of this evolution, the most relevant studies are with the most recent version (Xpresys Lung version 2 [now Nodify XL2]). One validation study on version 2 has been identified. The classifier has been designed to have high specificity for malignant pulmonary nodules, and the validation study showed a specificity of 97% for patients with a low-to-moderate pretest probability ($\leq 50\%$) of a malignant pulmonary nodule. The primary limitation of this study is that a high number of patients were excluded from the study due to incomplete clinical data or because they were subsequently determined to be outside of the intended use population. It is unclear if the intended use population was determined a priori. Validation in an independent sample in the intended use population is needed. No recent clinical validation studies were identified for the Nodify CDT test or the Nodify Lung testing strategy. The REVEAL validation study was a retrospective study that demonstrated use as a rule-out test in conjunction with the Veteran's Affairs (VA) Clinical Factors Model when the samples were considered inconclusive or intermediate risk by the VA model. The REVEAL model subsequently correctly identified 65% of intermediate-risk samples as either low or high risk. The negative predictive value and sensitivity were both 94%. Limitations included a small sample size and use in conjunction with just 1 type of testing model. Validation in an independent sample in the intended use population with additional probability models is needed. Indirect evidence suggests that a proteomic classifier with a high negative predictive value has the potential to reduce the number of unnecessary invasive procedures to definitively diagnose benign disease versus malignancy. However, long-term follow-up data would be required to determine the survival outcomes in patients with a missed diagnosis of lung cancer at earlier,

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

more treatable stages. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with undiagnosed pulmonary nodules following indeterminate bronchoscopy results for suspected lung cancer who receive gene expression profiling of bronchial brushings, the evidence includes multicenter prospective studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, morbid events, hospitalizations, and resource utilization. A 3-cohort, prospective, multicenter study validated the second generation Percepta Genomic Sequencing Classifier (GSC) test in an independent sample set, showing high sensitivity for the rule-out portion of the classifier and high specificity for the rule-in portion of the classifier. For intermediate pretest risk patients with an inconclusive bronchoscopy, Percepta GSC can down-classify the risk of primary lung cancer to low with a 91% negative predictive value, or up-classify the risk to high with a 65% positive predictive value. Further assessment of clinical utility is warranted. Also, where the test would fall in the clinical pathway (i.e., other than indeterminate bronchoscopy) is uncertain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

NA

VI. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as required by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

VII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational and therefore not covered:

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

Procedure Codes							
81479							

VIII. REFERENCES

[TOP](#)

1. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? *Diagnosis and management of lung cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May 2013; 143(5 Suppl): e93S-e120S. PMID 23649456
2. Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. *Sci Transl Med*. Oct 16 2013; 5(207): 207ra142. PMID 24132637
3. Vachani A, Pass HI, Rom WN, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. *J Thorac Oncol*. Apr 2015; 10(4): 629-37. PMID 25590604
4. Vachani A, Hammoud Z, Springmeyer S, et al. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules. *Lung*. Dec 2015; 193(6): 1023-7. PMID 26376647
5. Kearney P, Hunsucker SW, Li XJ, et al. An integrated risk predictor for pulmonary nodules. *PLoS One*. 2017; 12(5): e0177635. PMID 28545097
6. Silvestri GA, Tanner NT, Kearney P, et al. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. *Chest*. Sep 2018; 154(3): 491-500. PMID 29496499
7. Tanner NT, Springmeyer SC, Porter A, et al. Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2-Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. *Chest*. Mar 2021; 159(3): 1283-1287. PMID 33171158
8. Vachani A, Pass HI, Rom Wn, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. *Supplement. J Thorac Oncol*. April 2015;10(4):629-637.
9. Trivedi NN, Arjomandi M, Brown JK, et al. Risk assessment for indeterminate pulmonary nodules using a novel, plasma-protein based biomarker assay. *Biomed Res Clin Pract*. Dec 2018; 3(4). PMID 32913898
10. Pritchett MA, Sigal B, Bowling MR, et al. Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study. *PLoS One*. 2023; 18(7): e0287409. PMID 37432960
11. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: *Diagnosis and management of lung cancer*, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May 2013; 143(5 Suppl): e142S-e165S. PMID 23649436
12. Whitney DH, Elashoff MR, Porta-Smith K, et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. *BMC Med Genomics*. May 06 2015; 8: 18. PMID 25944280

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

13. Silvestri GA, Vachani A, Whitney D, et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. *N Engl J Med*. Jul 16 2015; 373(3): 243-51. PMID 25981554
14. Vachani A, Whitney DH, Parsons EC, et al. Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer. *Chest*. Jul 2016; 150(1): 210-8. PMID 26896702
15. Mazzone P, Dotson T, Wahidi MM, et al. Clinical validation and utility of Percepta GSC for the evaluation of lung cancer. *PLoS One*. 2022; 17(7): e0268567. PMID 35830375
16. Ferguson JS, Van Wert R, Choi Y, et al. Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer. *BMC Pulm Med*. May 17 2016; 16(1): 66. PMID 27184093
17. Lee HJ, Mazzone P, Feller-Kopman D, et al. Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study. *Chest*. Jan 2021; 159(1): 401-412. PMID 32758562
18. Detterbeck FC, Lewis SZ, Diekemper R, et al. Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May 2013; 143(5 Suppl): 7S-37S. PMID 23649434
19. Mazzone PJ, Sears CR, Arenberg DA, et al. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. *Am J Respir Crit Care Med*. Oct 01 2017; 196(7): e15-e29. PMID 28960111
20. National Comprehensive Cancer Network. NCCN Guidelines Version 3.2025: Non-Small Cell Lung Cancer. 2024
21. National Comprehensive Cancer Network. NCCN Guidelines Version 4.2025: Small Cell Lung Cancer. 2023
22. Biodesix. Nodify Lung: Lung Nodule Management. 2024
23. Veracyte. Percepta Genomic Sequencing Classifier for your patients. 2024

IX. POLICY HISTORY

[TOP](#)

MP 2.375	08/26/2020 New policy. Adopt BCBSA-Full adoption
	12/08/2021 Consensus Review. Updated FEP, background, and references. No changes to coding.
	12/01/2022 Administrative Update. New code 0360U effective 01/01/2023
	12/29/2022 Consensus Review. Updated background and references. Added 81479 to coding table.
	07/10/2023 Consensus Review. No change to policy statement. Policy Variation language updated. Background and Rationale updated. References added.
	01/19/2024 Administrative Update. Clinical benefit added.
	09/30/2024 Consensus Review. No change to policy statement. Background and Rationale updated. References added.
	01/24/2025 Administrative Update. Removed NCCN statement.

MEDICAL POLICY

POLICY TITLE	MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
POLICY NUMBER	MP 2.375

	07/09/2025 Consensus Review. No change to policy statement. Updated coding table, relocated codes 0080U, 0092U, 0360U to MP 2.277 & Removed 84999 from the policy.
	10/07/2025 Administrative Update. Removed Benefit Variations Section and updated Disclaimer.
	03/05/2026 Retirement Review. Service to be managed by the vendor Evicore

[TOP](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.